




iTind™ System

Reshaping BPH Treatment





1
Implantation



2
Treatment Period (5 to 7 days)



3
Removal



Before



After

The iTind™ device is a temporarily implanted nitinol device that reshapes the prostatic urethra and bladder neck to deliver significant and long-lasting relief of BPH symptoms^{2,3,4}, all without heating prostatic tissue or a permanent implant.

Through continuous pressure and subsequent ischemia and necrosis, the iTind™ device struts reshape the prostatic urethra and bladder neck, creating three deep longitudinal channels to allow for better urine flow. Patients are able to return home during the 5-7 day treatment, at the end of which the device is completely removed.

iTind™ therapy could benefit benefit men with BPH symptoms if they are:


- **Unsatisfied with drug therapy and not ready for surgery**
- **Concerned about permanent implants**
- **Wish to maintain sexual function**
- **Do not want a catheter post procedure**
- **May have a high and/or tight bladder neck**

Implantation of the iTind™ System may cause urinary urgency, pelvic discomfort, dysuria and hematuria. In rare cases, the iTind™ procedure may cause urinary tract infection and acute urinary retention.

Clinical Evidence – Scientific Publications¹

Clinical data demonstrates 3 year durability in results for both quality of life (IPSS) and maximum urinary flow (Qmax) using iTind for the treatment of BPH.²

- Rapid and effective symptomatic relief.^{2,3}
- Preserves sexual and ejaculatory function.^{2,3,4}
- Post-op catheterisation is rare.²
- Suitable alternative to prescription BPH medications.^{2,3}
- Suitable for treating high bladder neck.^{3,4}



Amparore et al., 2020^{2*}


- Multicenter prospective study on second generation iTind.
- Study sites: Italy, UK, Switzerland, Belgium, Hong Kong, Spain
- Number of patients: 81.
- Inclusion criteria: No age restriction; PV < 75 ml; IPSS ≥ 10; Qmax < 12 ml/sec.

Chughtai et al., 2020³

- Multicenter randomized, controlled trial on second generation iTind.
- Study sites: USA, Canada.
- Number of patients: 175 (randomized 2:1 between iTind and sham)
- Inclusion criteria: Age: ≥ 50 years; PV < 75 ml, IPSS ≥ 10; Qmax ≤ 12 ml/sec.

De Nunzio et al., 2020⁴

- Multicenter prospective study on second generation iTind.
- Study sites: Italy, Spain
- Number of patients: 70
- Inclusion criteria: No age restriction; PV < 120 ml; IPSS ≥ 10; Qmax < 12 ml/sec.



* Results shown were derived by per protocol analysis

References

1. Company sponsored trials under the responsibility of Medi-Tate.
2. Amparore D, Fiori C, Valerio M, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. *Prostate Cancer Prostatic Dis.* 2020.
3. Chughtai B, Elterman D, Shore N, et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. *Urology.* 2020.
4. De Nunzio C, Cantiello F, Fiori C, et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. *World J Urol.* 2020.
5. Medi-Tate. (2020) iTind System: *Instructions for Use*. Israel: Medi-Tate, Ltd. Retrieved from: <https://www.itind.com/ifu/>.

*Results shown were derived by per protocol analysis
Manufactured by Medi-Tate Ltd., 17 Hauman Street, Hadera, 3850169 Israel.
Specifications, design and accessories are subject to change without any notice or obligation on the part of the manufacturer.
Olympus is a registered trademark of Olympus Corporation, Olympus America Inc., and/or their affiliates. | Medical devices listed may not be available for sale in all countries.



OLYMPUS AUSTRALIA PTY LTD
3 Acacia Place, Notting Hill VIC 3168, Australia

OLYMPUS NEW ZEALAND LIMITED
28 Corinthian Drive, Albany, Auckland NZ 0632

For more information, contact your Olympus
sales representative at 1300 132 992
(Australia), 0508 659 6787 (New Zealand) or
www.olympus.com.au/medical/en